Chelsea and Westminster NHS Foundation Trust
chelwest.nhs.ukTotal trials
54
Active
7
Phase 3
3
Total enrollment
14,599
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Doravirine | — | — | — | — | 2 | ||
| Dolutegravir | — | — | — | — | 2 | ||
| Mifepristone | — | — | — | — | — | 1 |
Next readouts
- 2026-11-30
- 2026-12-31
Top conditions
- Human Immunodeficiency Virus4
- Burns3
- Coronavirus3
- Anxiety2
- Depression2
- Anesthesia2
- HIV2
- HIV-1-infection2
Frequently asked questions about Chelsea and Westminster NHS Foundation Trust
- How many clinical trials does Chelsea and Westminster NHS Foundation Trust have on ClinicalTrials.gov?
- Chelsea and Westminster NHS Foundation Trust is listed as the lead sponsor on 54 clinical trials in ClinicalTrials.gov, 7 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Chelsea and Westminster NHS Foundation Trust's trials are in Phase 3?
- 3 of Chelsea and Westminster NHS Foundation Trust's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Chelsea and Westminster NHS Foundation Trust focus on?
- Chelsea and Westminster NHS Foundation Trust's most-studied conditions on ClinicalTrials.gov are Human Immunodeficiency Virus, Burns, Coronavirus, Anxiety, Depression.
- When are Chelsea and Westminster NHS Foundation Trust's next clinical trial readouts?
- Chelsea and Westminster NHS Foundation Trust has 2 upcoming primary-completion readouts tracked here; the soonest is “Efficacy of Doravirine + Dolutegravir Dual Therapy in the Context of Antiretroviral Therapy Switch”, expected around 2026-11-30.